Conversely, duodenal adenocarcinomas had fewer BRAF (6.3% vs. 12.5%), PTEN (3% vs. 9%), and PIK3R1 (1% vs. 7.5%) gene alterations, as well as lower MSI-high rates (7.3% vs. 9%) and lower overall TMB (8.8 mutations/Mb vs. 11.3 mutations/Mb) compared to other small bowel subsites [1]. The gene discussed is BRAF; the disease is duodenal adenocarcinoma.